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Abstract
Background and Objective: Common mental disorders (CMD) are a leading global burden of
disease. Up to 30% of primary care attenders suffer from these disorders but most do not receive
evidence-based drug or psychological treatments. There are no trials of interventions which
attempt to integrate these treatments into routine primary care in developing countries. The aims
of this trial (the MANAS Project) are to evaluate the clinical and cost-effectiveness of a
collaborative stepped-care intervention for the treatment of CMD in India.
Study Design: A cluster randomized controlled trial will be implemented in the state of Goa, on
the west coast of India. Twenty-four primary care facilities, 12 from the government sector and 12
from the private sector, will be enrolled in two consecutive phases. For each sector, facilities will
be randomly allocated within strata defined by urban/rural location, population size and presence
of a visiting psychiatrist. Facilities will be randomly allocated to receive the collaborative stepped
care intervention or the enhanced usual care control intervention. Both arms share two
components of the intervention, viz., routine screening, and in the government clinics provision of
antidepressants. In addition, the collaborative stepped care arm also provides a range of
psychosocial treatments delivered by a specially trained Health Counselor, and supervision by a
visiting Psychiatrist. A total of 3600 primary care attenders who are detected to suffer from a CMD
based on a validated screening questionnaire will be recruited. The primary outcome is the
proportion of subjects who recover from an ICD10 defined CMD at baseline by 6 months.
Additional endpoints at 2 and 12 months will assess the speed and sustainability of achieving the
primary outcomes. Other outcomes will include recovery from ICD10 defined depression and
incidence of ICD-10 among individuals who were sub-threshold cases at baseline. Economic and
disability outcomes will be assessed to estimate incremental cost-effectiveness ratios.
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Implications: This will be the first trial of the effectiveness of a complex intervention aiming to
integrate efficacious treatments for CMD into routine primary care in a developing country. If
effective, its findings will have relevance to policy makers who wish to scale up treatments for CMD
in primary care across the world, but mostly in those countries where specialist mental health
services are few.
Study Registration: The MANAS project is registered through the National Institutes of Health
sponsored clinical trials registry and has been assigned the identifier: NCT00446407
Background
Common Mental Disorders (CMD) are depressive and
anxiety disorders which are typically encountered in com-
munity and primary care settings [1]. Although depressive
and anxiety disorders are classified as separate diagnostic
categories in ICD10[2], the concept of CMD is valid for
public health interventions due to the high degree of co-
morbidity between these disorders in primary care and
the similarity in epidemiological profiles and treatment
responsiveness [1,3-5]. In South-East Asia, 11% of Disa-
bility Adjusted Life Years and 27% of Years Lived with Dis-
ability are attributed to neuropsychiatric disease[6].
Depression is the most important neuropsychiatric cause
of disease burden [7] and CMD lead to profound levels of
disability through symptoms such as tiredness and sleep
problems, and are associated with increased health care
costs and reduced economic productivity [8-11].
The majority of persons with CMD in developing coun-
tries seek health care in primary care [7]. A review of 8 epi-
demiological studies of CMD in South Asia [12] showed
prevalence in primary care of 26.3% (95%CI 25.3%–
27.4%). Recognition is poor in primary care, with fewer
than 1/3rd of clinically significant morbidity detected[13].
Primary care doctors tend to prescribe a greater number of
symptomatic medications, such as injectable vitamins, for
patients with CMD [14]. A WHO multinational study in
general health care reported that nearly 10% of primary
care attenders with CMD in the Indian study centre were
prescribed psychotropic drugs[15]; however, the majority
of prescriptions were for tranquilizers (benzodiazepines)
rather than antidepressant drugs.
Three randomised controlled trials studying the efficacy of
treatments for CMD in India, Uganda, and Chile were
published recently [16-19] All the studies targeted poor
populations and tested treatment options that were
intended to be feasible, affordable, and acceptable to the
populations being studied. These trials attested to the effi-
cacy of antidepressants and brief psychological treatments
(interpersonal therapy), delivered in a stepped care
model. All the trials showed significant improvements in
disability levels in the intervention group; the Indian trial
also showed that treating CMD produces significant
reduction in total health care costs while the Chilean trial
found that the additional cost for each depression-free
day was roughly equivalent to the cost of a single bus fare
[20].
Although evidence of the efficacy of antidepressants and
brief psychological treatments has been available for dec-
ades[21], the scaling up of this evidence to routine pri-
mary care has been challenging [22-24]. Efforts to
improve the primary care treatment of CMD in developed
countries include the development of treatment guide-
lines for CMD and dissemination of guidelines via the
education of primary care providers[25,26]. Physician
education has been found to be associated with an
increase in the recognition of CMD, but not with lasting
improvements in patients' clinical outcomes [22,25]. Suc-
cessful quality improvement programs in developed
countries have included, in addition to improving recog-
nition rates, strategies which address other challenges
such as the chronic and recurrent nature of CMD and the
low adherence with evidence based treatments [27-31]. A
recent systematic review of the constituents of complex,
collaborative care interventions which improve effective-
ness for CMD [32] found that the use of routine screening
of all attenders and the professional background of staff
and specialist supervision predicted a favourable out-
come.
However, this effectiveness evidence cannot be readily
transferred to developing countries due to the widely dif-
ferent health systems. There are a number of obstacles to
scaling up efficacious interventions to the 'real-world' pri-
mary care context in developing countries [33-35]. The
first is the low recognition rate of CMD by primary care
doctors, for example because of somatic presentations
[36]. The second is the inadequate use of evidence-based
medications, including antidepressants (at inadequate
dosage or for too short durations), and the frequent use of
non evidence-based medications [37]. The third obstacle
is that few patients receive non-drug treatments for CMD,
typically because of the lack of human resources for psy-
chosocial treatments. There is also a severe shortage of
skilled mental health resources [38], and finally, low
adherence with treatments. Although training pro-
grammes for health workers often show an increase in
knowledge, the improvement in recognition rates areTrials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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transient [36], and translation to improved clinical out-
comes has not been evaluated [34,39]. Evidence from
mental health care demonstration projects show that
expansion of care to within reach of the majority of the
population in developing countries will necessitate
appropriately trained non-specialized health workers
working with specialized personnel [34]. The integration
of mental health in primary care is acknowledged as the
only feasible way of managing the burden of CMD in
developing countries [7] yet there is no evidence that such
care can be implemented effectively [34]. However, an
intervention which seeks to achieve this goal will need to
consider strengthening the human resources and support
for primary care practitioners, which will inevitably entail
increased financial investment. The potential that the
intervention will be scaled up may thus hinge on its cost-
effectiveness.
Design and Methods
Aims
We hypothesize that an intervention strategy based on a
Collaborative Stepped Care model, will be clinically- and
cost-effective, compared to Enhanced usual care control,
for the treatment of CMD and Depression in primary care
attenders. The hypothesis concerning cost-effectiveness is
important since the former intervention involves addi-
tional human resource inputs in a resource restricted envi-
ronment.
Objectives
The primary objective is to evaluate the impact of the
intervention on the proportion of subjects who recover
from an ICD10 defined CMD at 6 months follow-up. Sec-
ondary objectives include evaluating the impact of the
intervention among the sub-group of those who are suf-
fering from a Depressive Episode at baseline, the mean
CIS-R score among those who are probable (i.e. screen-
positive) cases at baseline, and the prevalence of ICD-10
CMD at 6 months among those who were sub-threshold
cases at baseline.
Setting
The study is being conducted in Goa, a state in west India
with a population of 1.4 million. Goa has been the setting
of studies on the epidemiology and treatment of CMD for
eight years [16,40-45]. It is estimated that at least 50% of
primary care in India (and in Goa) is delivered in the pri-
vate sector [46] and about half the population lives in
rural areas [47].
Study design
The stepped care model will be evaluated using a cluster-
randomized trial which will be implemented in two con-
secutive phases over 2 1/2 years beginning in April 2007.
Phase 1 involves 12 public facilities (Primary Health Cen-
tres or PHCs), 6 of which have been chosen at random to
deliver the stepped care model to patients screened posi-
tive for CMD with the other 6 "control" facilities deliver-
ing enhanced usual care control. Phase 2 will be
conducted in 12 private facilities (General Practitioners or
GPs).
Selection of facilities/randomisation
The sampling frame for phase 1 consisted of PHCs with
minimum space available for the intervention team and
which were not involved in preliminary phases related to
the intervention development, and which have at least
350 attenders per month. Facilities were stratified into
three strata; urban with a visiting psychiatrist (VP), rural
with a VP, rural without a VP. Two intervention and two
control PHCs were selected at random from each stratum,
using on-line software by the MANAS trial statistician
(HW) [48]. A given seed number was used to enable the
randomization procedure to be reproduced. This guards
against misallocation or changes in allocation at a later
stage. The sampling frame for phase 2 will consist of all
GPs with adequate clinic space and who consent to partic-
ipate, and will be similarly stratified.
The interventions
The collaborative stepped care (CSC) intervention
The model for the CSC intervention is based on the
stepped-care approach used in the Chilean trial [18]
which is ideally suited for treating CMD where a range of
severity is likely to be encountered. This approach empha-
sizes that while simple interventions such as recognition
and psycho-education may be provided to all participants,
more resource-intensive interventions such as antidepres-
sants and psychotherapy may be reserved for participants
who are severely ill or not responding to the simple inter-
ventions. Thus, the approach maximizes the efficient use
of health resources. Two general principles guide the
choice of intervention components: the use of evidence
based treatments for CMD; and the collaborations
between primary care medical and non-medical staff, and
between primary care and specialist staff. The intervention
consists of four key stages (recognition; treatment initia-
tion; follow-up and outcomes monitoring, and referral for
expert consultation if needed). These stages address spe-
cific obstacles to the integration of mental health in pri-
mary care. Examples of the specific components for each
stage of the intervention are presented in Table 1. The
steps in which they will be delivered are described in Table
2.
Screening is an essential component of our intervention,
ensuring relatively rapid recognition of CMD in this set-
ting where efforts to improve recognition through training
of doctors has not yielded sustainable improvement. Psy-
cho-education focuses on educating the person aboutTrials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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their symptoms, their association with CMD, the associa-
tion of CMD with personal difficulties, the need to share
emotional symptoms with the doctor and to share per-
sonal difficulties with caring family members or other key
persons in their social network. Psycho-education teaches
patients simple strategies for symptom alleviation. Our
choice of inter-personal therapy as the psychological treat-
ment is based both on its demonstrated feasibility and
effectiveness in another developing country [49], and on
its focus on interpersonal problems such as grief, disputes
and role transitions, which were consistent themes in the
adverse life experiences of participants in the earlier
research in Goa [50]. A minimum of 6 sessions, with an
optimum of 8 and a maximum of 12 sessions, will be
offered to each eligible participant. The choice of antide-
pressant is based on our earlier research which showed
better tolerance of low-cost SSRI (selective serotonin
reuptake inhibitors) such as fluoxetine [51], which was
also the antidepressant used in the previous Goa trial.
Fluoxetine is cheap in India, and has recently come off
patent globally. However, fluoxetine is not available in
PHCs and will therefore be provided by the project (to
integrate with the existing model of free medicines pre-
scribed by the PHC doctor). In the private GP phase, how-
ever, doctors will be free to use other antidepressants
which will need to be purchased by patients as they would
Table 1: Detailed steps of the collaborative stepped care intervention
Step For whom Timing Treatment BY WHOM
Recognition Adult PHC patients Before consultation with 
PHC doctor
Screening questionnaire; report for 
doctor
Health Assistant
1 Patients screened with CMD At first consultation Advice regarding screening 
questionnaire results; advice 
regarding seeing HC
Psychoeducation; follow up 
appointment within 2 weeks.
Yoga
PHC doctor
HC
HC
2 Patients who are severely ill 
at first consultation, or 
whose symptoms persist at 
follow-up
At first consultation or at 
follow up if not responding to 
Step 1
Antidepressants
OR start IPT in case the patient 
does not want Antidepressants
&
Adherence Management
PHC doctor
HC
HC
3 For participants who remain 
unwell, or are not adherent
Patients who do not respond 
to Step 2 despite taking the 
treatment
Antidepressants &
IPT &
Adherence Management
PHC doctor
HC
HC
4 For participants who do not 
respond despite good 
adherence
Patients who do not respond 
to Step 3 despite taking the 
treatment
&
Patients who are expressing 
suicidal ideas at any time
Continue all existing treatments
Refer to Clinical Specialist
HC & PHC doctor
Clinical Specialist
Table 2: Analysis groups
Group Definition Determined by Rationale Primary Outcome/s
Possible Cases Screen Positive CMD* GHQ12 score Feasible if rolled out and of 
significance to public health 
and primary care 
professionals – but includes 
30% false positives;
Prevalence of ICD10 
defined CMD* at 6 months
(primary)
Mean scores on CIS-R
(secondary)
Sub-Threshold Cases Screen Positive CMD*, but 
not ICD10 cases
CISR computer algorithm Sub-threshold cases who 
are at high risk of 
developing case-level CMD
Incidence of ICD10 CMD* 
in 6 months
(secondary)
Definite Cases ICD 10 defined CMD* CISR computer algorithm Narrower, biomedical 
category of significance to 
mental health professionals
Prevalence of ICD10 
defined CMD* at 6 months
(secondary)
Depression Cases ICD 10 defined depression CISR computer algorithm Narrower, severe 
biomedical category of 
significance to mental 
health professionals
Prevalence of ICD10 
defined CMD at 6 months
(secondary)
*(including anxiety disorders, mixed anxiety-depressive disorder, and Depression)Trials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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do with any other medicines prescribed by the GP. For
both antidepressants and psychotherapy, we have set a
priori  criteria for "minimum adequate" treatment. For
antidepressants, this criterion is use for at least 90 days at
a minimally adequate dose (at least 20 mg per day of
fluoxetine or the equivalent), and for IPT, attendance at
least six sessions.
The intervention was developed in a systematic three-
stage preparatory phase over 15 months, which has been
described in detail previously [52]. The intervention will
be delivered by four key persons in each facility: a Health
Assistant, a Health Counselor (HC); the primary care doc-
tor/s; and a psychiatrist in the role of Clinical Specialist.
The Health Assistant will screen adult patients attending
the PHC using the 12 item General Health Questionnaire
(GHQ) [53] to identify those who are suffering from a
CMD and report the results to the PHC doctor. The choice
of the GHQ was based on a study evaluating five possible
screening questionnaires carried out as preparation for the
trial [54]; the GHQ was found to have the highest discrim-
inating properties, both for CMD as a broad clinical cate-
gory and for the narrower category of Depressive Episode.
The HC will lead the intervention. She will be a locally
recruited graduate non-medical worker who will take
overall responsibility for the intervention in close collab-
oration with the primary care doctor; she will deliver all
the non-drug treatments. The principal role of the primary
care doctors will be to initiate antidepressant treatments
and provide usual care for any co-existing physical health
problems. Each facility team will be supported by a Clini-
cal Specialist, a psychiatrist who will act as a specialist
resource person to train and support the primary care doc-
tors and the HCs. Details of the intervention can be found
in Table 3 and in the publication describing its develop-
ment [52].
The enhanced usual care control (EUC) intervention
In order to assemble comparable samples of patients in
the intervention and control practices, it is necessary to
conduct systematic screening in both groups. If we are
screening in the usual care practices, it is unethical to con-
ceal screening results from treating physicians. Conse-
quently, physicians in usual care practices will receive
screening results and may choose to initiate treatment.
This enhancement to usual care in the control practices
may introduce a conservative bias, i.e. reducing the differ-
ence in outcomes between intervention and control prac-
tices, but it is ethically necessary. This will be introduced
in control facilities. They will have only one additional
staff, viz. the Health Assistant, who will screen patients for
CMD, and fluoxetine will be provided by the project to
PHCs but not to private GP practices, as in the Collabora-
tive Stepped Care arm.
We do not anticipate a significant risk of contamination,
i.e. patients moving from an Enhanced usual care control
facility to an intervention facility, due to the geographical
spread of facilities, and because no publicity will be pro-
duced regarding the availability of the intervention in
other facilities. In addition, we do not anticipate a signifi-
cant therapeutic effect in the Enhanced usual care control
arm given that screening and recognition, or the provision
of evidence based guidelines, are not, by themselves, suf-
ficient to lead to clinical improvements [22,25].
Selection of study participants
The flowchart for selection of trial participants is shown in
Figure 1. Eligibility criteria for screening by the Health
Assistant are: age >17 years, not requiring urgent medical
attention, not already screened in the previous 2 weeks;
and not already receiving the intervention. All patients
who screen positive (GHQ score >5) will be notified to
the GP, and eligible to receive whichever intervention pro-
gramme is being delivered in the facility. Those who, in
addition, fulfill the following criteria will be invited to
participate in the outcome evaluation of the trial: resident
in Goa for the subsequent 12 months; speak one of the
three primary study languages (Konkani, Marathi, Eng-
lish); and do not suffer from a serious impairment (hear-
ing, speech, cognition) which interferes with participation
in an interview. If the patient gives written or verbal con-
sent, the Health Assistant will carry out a structured clini-
Trial Flow Chart: selection of participants in each facility Figure 1
Trial Flow Chart: selection of participants in each facility.
Consecutive attenders >17 years of age; not already receiving/received intervention; not 
been screened in previous 2 weeks; not requiring urgent hospital referral 
Screening with GHQ; if score>5 
Resident for the subsequent 12 months in Goa and speaking Konkani/Marathi/English 
and not suffering from speech/hearing/cognitive impairment 
Yes No
Informed Consent for participation in trial 
Yes No
Diagnostic interview (CISR) 
Intervention         Intervention 
Process Indicators       Process  Indicators
Outcome evaluation at 2, 6 & 12 months Trials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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cal diagnostic interview (the Revised Clinical Interview
Schedule or CIS-R) [55] which has been previously field
tested in Goa [56].
Trial objectives and outcomes
It is our objective to study the overall effect of the inter-
vention on the treatment and outcome of CMD in pri-
mary care. Four primary research questions are being
addressed in the trial, relating to clinical outcomes in dif-
ferent groups of patients, defined according to their type
of CMD at baseline (Table 2). From a practical or policy
perspective, we need to evaluate the impact on all patients
who are identified on the basis of the short screening pro-
cedure. Our primary analysis will focus on the subgroup
for whom previous evidence is clearest regarding benefit:
definite ICD-10 CMD. The outcome will be assessed
through home visits at 6 months using the CISR which
generates both CMD case and Depression case outcomes
based on ICD10 criteria; and a CISR total score. Six
months is chosen as the primary endpoint because it
marks the maximum duration of the first-line drug and
psychological components of the intervention. Other
end-points at 2 and 12 months will assess the rate and
persistence of clinical recovery. Other outcomes include
recovery from Depression, the mean CIS-R score, and
prevalence of ICD-10 among sub-threshold cases (Table
2).
In addition, economic costs and outcomes will be meas-
ured using the Costs of Illness Schedule, developed for
economic analyses of mental disorders in India [9] and
used in the previous efficacy trial in Goa [16]. This sched-
ule includes both direct and indirect costs, due to health
problems, incurred by the participants, but does not
include the direct costs of the intervention itself. The latter
will be computed by deriving a monetary value for each
component of the intervention based on actual costs, and
applying these to each individual based on the process
indicators which reflect the actual contact with the inter-
vention. Disability levels will be assessed using the
WHO12 item Disability Assessment Schedule, based on
the Brief Disability Questionnaire which has been used in
Goa [14,57], and input into the estimation of opportunity
costs.
Outcome evaluation/masking
Outcomes will be assessed through home visits by a team
of researchers independent of the intervention team and
blind to the allocation status of the patient. The primary
end-point assessment will occur within a month of the 6
month follow-up date; similarly for the 2 and 12 month
assessments. Masking will be maximized by:
• Randomly allocating unique patient IDs so that there is
no association between the ID number and the facility
identity.
• Ensuring that the outcome evaluation is carried out by
an independent institution whose team is not privy to the
randomization allocation.
• Emphasizing to assessors that all patients are receiving
an intervention (not specifying whether this is enhanced
care or Collaborative Stepped Care) and that there is gen-
uine equipoise about which is better
• Carrying out CISR (the primary outcome) assessments
prior to all other outcome assessments.
• Assessing the efficacy of blinding (through asking asses-
sors to guess which arm the participant is allocated to) at
the end of the trial
• Ensuring that process and qualitative research evalua-
tions (not described in this protocol) are carried out inde-
pendently of the quantitative evaluations; the qualitative
research will be carried out only with participants who
have consented, but who are not selected for the quantita-
tive evaluation.
• Inserting a 'dummy' question at the 6 month follow-up
which assesses a health state (fever) which is not influ-
enced by the intervention.
Sample size
a) Definite cases
150 participants with a GHQ score >5 will be recruited
from each of 24 facilities. Based on the piloting stage expe-
rience that up to 25% of these participants will either not
be traced by the outcome evaluators or will not consent to
participate, and that at least 1 in 3 'cases' identified by the
GHQ are Sub-Threshold cases, we anticipate that at least
75 definite cases (see Table 3) from each facility will com-
plete the outcome evaluation at the 6 month end-point.
This gives a total sample size of 1800 in which to assess
our primary outcome: recovery rate of ICD-10 defined
CMD at 6 months among definite cases at baseline. This
will have more than 90% power to detect at the 5% level
of significance a difference in recovery rates of 70% in the
Collaborative Stepped Care versus 50% in the Enhanced
usual care control arm. If the recovery rates are 65% and
50% respectively, we will have 74% power to detect a sig-
nificant difference. Similarly, we have around 90% power
to detect a difference in proportion recovered from
depression at 6 months of 50% in the Collaborative
Stepped Care arm versus 30% in the Enhanced usual care
arm.Trials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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The assumptions underlying this calculation are as fol-
lows. The recovery rates in the Chilean trial [18], whose
intervention model is the one being used in this study,
showed a gap in recovery at 6 months of 70% versus 30%
between the two groups. However, our trial is evaluating
effectiveness of introducing this model into routine care,
and so we would expect a smaller difference between rates
than in an efficacy trial. Furthermore the Chilean trial
focused on Depression, while ours will also recruit sub-
jects with less severe CMD who might potentially have
higher spontaneous recovery rates in both treatment arms.
There are no existing data on the recovery rates of CMD in
routine PHC or GP in India. The limited data from other
developing countries, including outcomes of Usual Care
groups in efficacy trials, suggests that between 30% and
50% of subjects with a CMD recover without active inter-
vention by 6 or 12 months after recruitment [16,18,58].
We therefore based our primary sample size calculation
on a likely conservative difference of 20% between the
two arms (compared to 40% in the Chile trial), and on
recovery rates of 30–50% in the Enhanced usual care con-
trol arm.
A key factor in estimation of the sample size for a cluster
RCT is the coefficient of variation (SD/mean) of the true
proportions with the outcome between clusters within
each arm [59]. In the absence of outcome data to estimate
k in Goa, we have used the recovery rates of CMD in the
two Asian centres (Shanghai, Bangalore) of the WHO
multinational study of CMD in general health care [10],
and data from 8 studies of CMD prevalence in India (two
in urban GPs, three in urban PHCs and three in rural
PHCs) [12] all of which estimate k < 0.2. The proposed
trial is located in one state of India and facilities are strat-
ified according to their rural/urban location and private/
public sector; hence the value of k is likely to be even
lower [59,60]. To be conservative, we have used an esti-
mate of k = 0.2.
b) Possible cases
We expect about one-third of possible cases to be sub-
threshold cases at baseline, as defined by the CIS-R, and
that 10% of these might become new cases in the EUC
arm compared to 5% in the CSC arm. In addition, we
assume that 50% of the definite cases at baseline will still
be cases at 6 months in the control arm, compared to 30%
in the intervention arm. So overall, we will expect preva-
lence of CMD at 6 months amongst possible cases at base-
line to be 37% in the control arm (10% × 1/3rd + 50% ×
2/3rd), and 22% in the intervention arm (5% × 1/3rd +
50% × 2/3rd). We will have 99% power to detect this dif-
ference at the 5% significance level, assuming a 75% fol-
low-up rate as above.
A secondary outcome in this group is the mean CIS-R
score at 6-months among probable, i.e. screen-positive,
cases at baseline. Our earlier longitudinal study of con-
firmed ICD10 cases at baseline found a reduction in mean
CISR score of 50% over 6 months from 24 (s.d. 6) to 12
(s.d. 10) [16]. We would expect slightly lower CISR scores
among all possible cases at baseline in our study. Our
sample size gives high power (100%) to detect a differ-
ence in CIS-R score at 6 months of 18 (s.d. 10) in the
Enhanced usual care control arm versus a CIS-R score of 9
(s.d. 10) in the Collaborative Stepped Care arm.
c) Sub-threshold cases
The only cohort study of primary care attenders which has
reported on risk factors for new cases of CMD from a
developing country was carried out in Zimbabwe [61]; in
this study, the proportion of sub-threshold cases at base-
line who became cases at 6 months was 31% (19 out of 61
subjects). Assuming a 75% follow-up rate we will have an
effective sample size of 900 sub-threshold cases; this gives
about 70% power to detect a difference in the proportion
with CMD at 6 month follow-up between 5% in the inter-
vention arm and 10% in the control arm.
d) Depression cases
Our pilot data has shown that only 1/3 of CMD cases are
suffering from ICD-10 depression. Thus the proposed
sample size would yield about 25 depression cases per
facility traced at 6 months, giving a total effective sample
size of 600; this has 94% power to detect a difference in
recovery rates of 30% in the Enhanced usual care control
arm and 50% in the Collaborative Stepped Care arm at 6
months. Again these are conservative estimates compared
to the achievements of the Chile trial.
e) Cost effectiveness
We have not powered our trial for the cost-effectiveness
outcome because we expect the intervention to be domi-
nant as compared to the usual care, i.e. improved out-
comes  and  lower costs. Thus, additional resources
required to implement the intervention are expected to be
fully or partially offset by reduced consumption and asso-
ciated costs of other health care services (especially outpa-
tient attendance for somatic symptoms) and to also lead
to reduced opportunity costs to patients and families
(especially lost work days). This is what we found for the
antidepressant arm in the earlier cost-effectiveness trial in
Goa [16].
Data management & analyses
Data will be collected using a hand-held computer (Palm-
OS), and exported to Stata 9.0 for statistical analysis.
Given direct entry of responses, we expect there to be min-
imal data entry errors. Findings will be reported as per the
CONSORT guidelines for cluster randomized controlledTrials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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trials [62]. Baseline comparability will be assessed for
individuals who did not consent to be part of the trial, and
of participants who could and could not complete review
assessments. Comparability of the two intervention arms
will be assessed for a variety of potential confounding fac-
tors assessed at 2 months, notably: age, sex, education, per
capita income, severity of mental health scores, ICD10
diagnostic distribution, and comorbidity with alcohol use
and physical health problems.
The primary analyses will be intention-to-treat, regardless
of adherence to the intervention, and will be based on
outcomes 6 months after diagnosis. Logistic regression
generalized estimating equations with robust standard
errors will be used to compare case prevalence in the two
arms, allowing for any within-facility clustering resulting
from the cluster randomized design [63], and adjusting
for baseline mental health score. Further analyses will
adjust for any other of the a-priori defined confounding
factors list above for which randomization did not
achieve balance between the two arms at baseline. These
analyses will be carried out for the different patient groups
defined in Table 3, with their respective outcomes as
described above. For each of these primary outcome anal-
yses, we will present an estimate of the effect size as an
odds ratio and 95% confidence intervals, and a coefficient
of intracluster correlation. A number of secondary analy-
ses are proposed, which are listed in the Trial Registration
protocol.
For the economic analysis, health care costs and other
patient- or family-borne costs will be computed and com-
pared at 2, 6 and 12 months, and subsequently related to
changes in health outcome: both the primary outcome
measure of depression status and also Quality Adjusted
Life Years (QALYs). A culturally specific and conceptually
solid utility measure for depression – necessary for the
estimation of QALYs – will be generated by relating health
state valuation scores (taken from an Indian population
as part of a wider WHO multi-country study) to summary
scores on the WHO-DAS. In the event that dominance is
not shown, i.e. the intervention is more effective but the
costs are also more than the usual care group, we will esti-
mate the probability of dominance and estimate incre-
mental net benefit and incremental cost-effectiveness
ratios. The latter will be computed, together with their
confidence intervals (using bootstrapping techniques to
overcome expected skewness of cost data). Cost-effective-
ness acceptability curves will also be derived in order to
show the probability of any cost-effective advantages for
the component interventions at a range of 'willingness to
pay' threshold levels.
Trial monitoring
The following 'sentinel' outcome data will be recorded
upon completion of interviews for monitoring and safety
requirements, and reported to the Trial Steering Commit-
tee and Data Monitoring & Ethics Committees at least
quarterly: number and proportion of completed outcome
assessments and refusals; ICD10 case status for any CMD
and Depression; hospitalizations; suicide attempt; and
deaths.
No stopping rules are proposed because serious adverse
events are not expected in the trial since none of the treat-
ments being offered are experimental or associated with
serious outcomes. A recent systematic review has shown
that RCTs stopped early show implausibly large treatment
effects and that there needs to be a balance between the
ethical concerns of safeguarding interests of patients who
have been randomized in the trial while also "protecting
society from overzealous premature claims of treatment
benefit [64,65]." Furthermore, the trial will proceed to
phase 2 (GP facilities) without conducting formal interim
analyses at the end of phase 1 (PHC facilities) since, even
if such analyses showed considerable impacts of the inter-
vention, these may not be generalizable from PHC to GP
facilities.
Ethical considerations
While the efficacy of specific intervention components
(e.g., anti-depressant drugs) is established in developing
countries, the same is not true for the effectiveness of
intervention strategies that attempt to introduce these
into usual primary care. The proposed trial is addressing
whether a collaborative stepped-care intervention enables
these treatments to be provided effectively in primary care
and, if so, what are the marginal benefits and costs. There
is genuine clinical equipoise concerning this research
question in the context of developing countries where the
intervention presents additional costs and where there are
several other public health priorities. Under-powered tri-
als are unethical for patients [66]; our sample size calcula-
tions are therefore based on conservative estimates and
high power. No participant will be deprived of any treat-
ment s/he would ordinarily receive. Participants in the
enhanced usual care control facilities may benefit as a
consequence of the screening and, in the PHCs, the provi-
sion of antidepressants to the pharmacy. Thus they will be
provided with the results of the screening questionnaire
and those who remain ill at 12 months will be offered psy-
chiatric consultation by the Clinical Specialist. In addi-
tion, if any trial participant (in either arm) is found to
have attempted suicide (assessed during outcome evalua-
tion), the field work team will report this through an
administrator to the intervention team who will make
arrangements to provide psychiatric care for the partici-
pant. Explicit referral guidelines will be provided to doc-Trials 2008, 9:4 http://www.trialsjournal.com/content/9/1/4
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tors in the Enhanced usual care control arm for patients
who may be suicidal or need specialist advice (to the local
public psychiatric services available in three hospitals in
Goa).
In cluster RCTs, consent for participation in a trial is
needed both from the clusters and, depending on the type
of intervention being delivered and outcomes assessed,
from individual participants. In the MANAS trial, cluster
level consent is being obtained as follows:
• Phase 1: PHC consent has been obtained in two steps;
first, the Government of Goa's Directorate of Health Serv-
ices; after the final 12 PHCs were identified and rand-
omized, specific written consent was obtained from the
DHS for the participation of these 12 PHCs.
• Phase 2: Individual facility level consent from each GP
is implicit since only those who are consenting to partici-
pate will be included in the sampling frame.
Individual participant consent is being obtained in two
stages: after the screening, those who are screen-positives
will be invited to participate in the CIS-R interview and
thereby be enrolled in the trial; and for those selected for
outcome evaluation, formal written consent will be
obtained by the field researcher at the first visit to the par-
ticipant in his/her home 2 months after enrollment.
Formal ethical approval has been obtained from the IRBs
of the lead Goan organization (Sangath) and the London
School of Hygiene & Tropical Medicine and has been
approved by the Indian Council for Medical Research. The
Trial Steering and Data Monitoring & Ethics Committees
will monitor the progress of the trial. A fresh report will be
made to both ethics committees of major changes in the
protocol since the original proposal was assessed.
Discussion
While there is evidence on what treatments work for CMD
in developing countries, the question of how these can be
effectively delivered in routine primary care remains
unanswered [67]. This is one of the major research priori-
ties in global mental health [68]. The results of the trial
will be used to inform policy makers and practitioners in
developing countries on the practical implementation,
and the clinical and economic benefits of improving the
management of CMD in primary care. The trial is likely to
yield findings which are generalisable beyond the popula-
tion of the study and, if effective, could be scaled up in
health policy due to: the representative sampling of partic-
ipants from rural and urban, private and public primary
care facilities; the use of an intervention strategy which
integrates evidence from efficacy trials from three devel-
oping countries and emphasizes acceptability (to practi-
tioners, policy makers and participants), affordability
(acceptable cost-effectiveness ratio) and availability (use
of locally available resources); and the application of
methods to address obstacles to the integration of mental
health in primary care.
We acknowledge that the trial intervention will not tackle
all the obstacles to the integration of mental health in pri-
mary care, such as the stigma associated with mental ill-
ness in the community [33,35]. Some components of the
intervention may not seem generalisable. First, is screen-
ing a feasible component of the intervention? Recognition
of CMD is an essential requirement for providing an inter-
vention. A strictly naturalistic trial may have chosen to
recruit subjects referred by the primary care doctor. We
ruled this out since there is good evidence to show that
recognition rates are very low [10,12,14,56] and that
training doctors does not lead to sustainable higher rates
of recognition[33]. Furthermore, a recent systematic
review of collaborative care interventions found system-
atic identification of patients was one of only three spe-
cific ingredients which predicted a favorable response to
the intervention [32]. Thus, screening in this trial is an
integral component of the intervention as well as being
used to identify a comparable sample of CMD patients in
the Enhanced usual care control arm. With regards to scal-
ing up, we believe that screening is feasible because of the
high prevalence of CMDs in primary care attenders, the
brevity of screening instruments (which may be reduced
to just a couple of questions) [69] and the increasing liter-
acy rates in many countries which makes self-completion
feasible. The second component is that of the need for
employment of a Health Assistant and a Health Coun-
selor, additional human resources, in primary care facili-
ties. However, the type of persons we will use in this role
is relatively low-cost. Such persons who might suit these
roles are easily available in most developing countries and
could perform other roles, such as behaviour modifica-
tion and lifestyle interventions for other chronic diseases.
If Ministries of Health are to consider supporting mental
health programmes which involve additional resources,
data on the feasibility and cost-effectiveness of interven-
tions are critical [34]; the proposed trial will provide the
first systematic evidence of this kind from a low income
country.
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